Effect of Sitagliptin on Serum Irisin Levels in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
Open Access
- 24 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetes Therapy
- Vol. 12 (4), 1029-1039
- https://doi.org/10.1007/s13300-021-01023-z
Abstract
Introduction Irisin is a unique myokine with striking effects on regulating insulin sensitivity and energy metabolism. This study aimed to investigate the changes in serum irisin in patients with newly diagnosed type 2 diabetes mellitus (T2DM) following sitagliptin treatment. Methods Thirty-two patients with T2DM were treated with 100 mg/day sitagliptin for 16 weeks. Twenty age-, sex- and body mass index (BMI)-matched healthy subjects were enrolled as the control group. Irisin and metabolic parameters were measured at baseline and after treatment. Results Patients with T2DM had lower irisin levels than the controls (10.03 ± 2.06 vs. 13.06 ± 3.10 ng/ml, P < 0.01). Sitagliptin treatment significantly increased serum irisin levels in T2DM patients compared to baseline (11.18 ± 1.91 vs. 10.03 ± 2.06 ng/ml, P < 0.01). Increased irisin levels were associated with decreased fasting blood glucose (FBG) (β = − 0.24, P < 0.05) and glycosylated hemoglobin (HbA1c) (β = − 0.15, P < 0.05). Conclusions Sitagliptin treatment significantly increased serum irisin levels in patients with T2DM, and the increase of the irisin level was associated with decreases of FBG and HbA1c levels. These results suggest that irisin might be involved in the antidiabetic mechanisms of sitagliptin. Trial Registration ClinicalTrials.gov identifier NCT04495881.Funding Information
- National Natural Science Foundation of China (81770792)
- Beijing Municipal Commission of Education (KZ201810025038)
- Beijing Municipal Excellent Talents Foundation (2018-12)
This publication has 33 references indexed in Scilit:
- Plasma irisin depletion under energy restriction is associated with improvements in lipid profile in metabolic syndrome patientsClinical Endocrinology, 2013
- Lower circulating irisin is associated with type 2 diabetes mellitusJournal of Diabetes and its Complications, 2013
- Serum irisin levels in new-onset type 2 diabetesDiabetes Research and Clinical Practice, 2013
- Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trialDiabetes, Obesity and Metabolism, 2012
- A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesisNature, 2012
- Protective Effects of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor against Increased β Cell Apoptosis Induced by Dietary Sucrose and Linoleic Acid in Mice with DiabetesOnline Journal of Public Health Informatics, 2011
- Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptinDiabetes, Metabolic Syndrome and Obesity, 2010
- Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes*Diabetes, Obesity and Metabolism, 2008
- Homeostasis Model Assessment (HOMA) as Surrogate Insulinization Criteria in Patients With Type 2 DiabetesClinical Journal of Sport Medicine, 2008
- Tissue-Specific Knockout of the Insulin Receptor in Pancreatic β Cells Creates an Insulin Secretory Defect Similar to that in Type 2 DiabetesCell, 1999